Drug or treatment

Pacritinib clinical trials

• 18Clinical trials
• 8Countries

Newest trials

All recruiting trials (18)

• Pacritinib Effectiveness in Real-world Settings

  This real-world study will see how pacritinib works for adults with myelofibrosis by looking back at medical records from several centers.

  Recruiting at 5 sites Swedish Orphan Biovitrum · New Haven, Connecticut and 4 other locations · NCT07774455

• Pacritinib and Selinexor in JAK-inhibitor naive myelofibrosis with anemia and low platelets

  This trial tests whether combining pacritinib and selinexor helps patients with myelofibrosis who have anemia and low platelets and have not yet tried a JAK inhibitor.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · Westwood, Kansas and 2 other locations · NCT07447817

• Pacritinib for bone marrow fibrosis in myelofibrosis with low platelets

  This trial will test if pacritinib can reduce bone marrow fibrosis and help restore blood counts in adults with myelofibrosis who have low platelets (50–120 × 10^9/L).

  Recruiting at 12 sites Phase 2 Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas · Barcelona, Barcelona and 12 other locations · NCT07394153

• Pacritinib for metastatic castration-resistant prostate cancer after ARSI

  This trial tests pacritinib in adults with metastatic castration-resistant prostate cancer that has progressed after ARSI treatment to see if the drug can help.

  Recruiting Phase 2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT07226713

• Pacritinib plus azacitidine or decitabine to help people with accelerated or blast‑phase myeloproliferative neoplasms reach stem cell transplant.

  This trial tests if adding pacritinib to standard azacitidine or decitabine helps adults with accelerated or blast‑phase myeloproliferative neoplasms get to allogeneic stem cell transplant.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07148947

• Pacritinib versus Hydroxyurea for advanced proliferative chronic myelomonocytic leukemia

  This trial tests whether pacritinib works better than hydroxyurea for adults with advanced proliferative chronic myelomonocytic leukemia.

  Recruiting at 6 sites Phase 2 Theradex · Tampa, Florida and 5 other locations · NCT07033598

• Pacritinib for relapsed or refractory Waldenström macroglobulinemia

  This trial will test whether the oral drug pacritinib can safely reduce disease and symptoms in adults whose Waldenström macroglobulinemia has returned or did not respond to prior treatment.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06986174

• Assessing the effectiveness of pacritinib for VEXAS syndrome

  This study is testing if the drug pacritinib can help people with VEXAS syndrome manage their symptoms better while reducing their need for steroids.

  Recruiting at 2 sites Phase 2 Swedish Orphan Biovitrum · Scottsdale, Arizona and 38 other locations · NCT06782373

• Pacritinib combined with a BTK inhibitor for relapsed or refractory mantle cell lymphoma

  This study tests whether adding pacritinib to a BTK inhibitor is safe and can help adults whose mantle cell lymphoma has returned or not responded to prior treatments.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06675123

• Using pacritinib to treat VEXAS syndrome

  This study is testing if the drug pacritinib can help people with VEXAS syndrome feel better and manage their symptoms.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT06538181

• Tagraxofusp plus pacritinib for intermediate- or higher-risk myelofibrosis after JAK inhibitor therapy

  This trial will test whether combining Tagraxofusp with pacritinib helps adults with intermediate‑ or higher‑risk myelofibrosis who have tried or cannot take approved JAK inhibitors.

  Recruiting Early Phase 1 University of Kansas Medical Center · Fairway, Kansas · NCT06414681

• Pacritinib for adults and adolescents (12+) with myelodysplastic syndromes or MDS/MPN

  This study will try the oral medicine pacritinib in people aged 12 and older with MDS or MDS/MPN to see if it helps their disease.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06303193

• Combining Pacritinib and Talazoparib for Patients with Myeloproliferative Neoplasms Not Responding to JAK2 Therapy

  This study is testing a combination of two medications, pacritinib and talazoparib, to see if they can help patients with certain blood cancers who haven't responded to other treatments.

  Recruiting Phase 1 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT06218628

• Using pacritinib with azacitidine for treating chronic myelomonocytic leukemia

  This study is testing if a new combination of two medications, pacritinib and azacitidine, can help people with chronic myelomonocytic leukemia feel better and improve their treatment outcomes.

  Recruiting Phase 1/2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT06159491

• Testing pacritinib for treating KSHV-related diseases

  This study is testing if the drug pacritinib can help people with KSHV-related diseases like Kaposi sarcoma and multicentric Castleman disease feel better and reduce inflammation.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06052618

• Testing pacritinib for treating severe chronic graft-versus-host disease after stem cell transplant

  This study is testing if a new oral medication called pacritinib can help adults with severe chronic graft-versus-host disease who haven't found relief from other treatments.

  Recruiting at 2 sites Phase 1/2 National Institutes of Health Clinical Center (CC) · Miami, Florida and 1 other locations · NCT05531786

• Using pacritinib to treat relapsed or refractory T-cell lymphoproliferative neoplasms

  This study is testing if the oral medication pacritinib can help people with certain types of T-cell lymphomas that have come back or didn’t respond to other treatments.

  Recruiting at 4 sites Phase 2 University of Michigan Rogel Cancer Center · Duarte, California and 5 other locations · NCT04858256

• Combining decitabine with ruxolitinib, fedratinib, or pacritinib for treating advanced myeloproliferative neoplasms

  This study is testing if combining decitabine with other medications can help patients with advanced blood cancers get ready for a stem cell transplant.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT04282187

Quick answers

How many clinical trials of Pacritinib are recruiting right now?

18, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 8 countries. The most sites are in United States (17 trials), Spain (2 trials), United Kingdom (2 trials), Canada (1 trial), France (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 10, Phase 1: 3, Phase 1/2: 3, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →